Chronic treatment in vivo with β-adrenoceptor agonists induces dysfunction of airway β 2-adrenoceptors and exacerbates lung inflammation in mice

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2365-2377

  Lin, Rui ^a   Degan, Simone ^a   Theriot, Barbara S ^a   Fischer, Bernard M ^a   Strachan, Ryan T ^a   Liang, Jiurong ^a   Pierce, Richard A ^b   Sunday, Mary E ^a   Noble, Paul W ^a   Kraft, Monica ^a   Brody, Arnold R ^c   Walker, Julia K L ^a  

^a DUKE UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

adrenoceptor; agonist; airway inflammation; airway remodelling; asthma; loss of bronchoprotection; mouse; receptor desensitization

Indexed keywords

ALLERGEN; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYTOKINE; SALBUTAMOL;

AIRWAY REMODELING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; BRONCHOPROTECTION; CONTROLLED STUDY; DESENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE DELETION; IN VIVO STUDY; LIGAND BINDING; LONG TERM CARE; LUNG DISEASE; LUNG LAVAGE; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; RESPIRATORY TRACT DISEASE;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHOCONSTRICTION; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OVALBUMIN; PNEUMONIA; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84863418512     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01725.x     Document Type: Article

References (67)

1. Abisheganaden J, Boushey H, (1998). Long-acting inhaled beta 2-agonists and the loss of 'bronchoprotective' efficacy. Am J Med 104: 494-497. (Pubitemid 28274856)
2. Baker JG, (2005). The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144: 317-322. (Pubitemid 40313677)
3. Barnes PJ, (2008). The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 118: 3546-3556.
4. Bateman E, Nelson H, Bousquet J, Kral K, Sutton L, Ortega H, et al,. (2008). Meta-analysis: effects of adding salmeterol to inhaled corticosteroids on serious asthma-related events. Ann Intern Med 149: 33-42.
5. Bergeron C, Hauber HP, Gotfried M, Newman K, Dhanda R, Servi RJ, et al,. (2005). Evidence of remodeling in peripheral airways of patients with mild to moderate asthma: effect of hydrofluoroalkane-flunisolide. J Allergy Clin Immunol 116: 983-989. (Pubitemid 41571776)
6. Bhagat R, Kalra S, Swystun V, Cockcroft D, (1995). Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 108: 1235-1239.
7. Bond RA, (2001). Is paradoxical pharmacology a strategy worth pursuing? Trends Pharmacol Sci 22: 273-276. (Pubitemid 32523909)
8. Callaerts-Vegh Z, Evans KLJ, Dudekula N, Cuba D, Knoll BJ, Callaerts PFK, et al,. (2004). Effects of acute and chronic administration of β-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci U S A 101: 4948-4953. (Pubitemid 38469183)
9. Cazzola M, Calzetta L, Matera MG, (2011). β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 163: 4-17.
10. Cheung D, Timmers M, Zwinderman A, Bel E, Dijkman J, Sterk P, (1992). Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma [see comments]. N Engl J Med 327: 1198-1203.
11. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC, (1993). Regular inhaled salbutamol and airway responsiveness to allergen. Lancet 342: 833-837. (Pubitemid 23285911)
12. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al,. (2000). Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Lancet 355: 1675-1679. (Pubitemid 30248479)
13. Deshpande DA, Penn RB, (2006). Targeting G protein-coupled receptor signaling in asthma. Cell Signal 18: 2105-2120. (Pubitemid 44636173)
14. Deshpande DA, Theriot BS, Penn RB, Walker JKL, (2008). β-arrestins specifically constrain β2-adrenergic receptor signaling and function in airway smooth muscle. FASEB J 22: 2134-2141. (Pubitemid 351948632)
15. Dickey BF, Walker JK, Hanania NA, Bond RA, (2010). β-adrenoceptor inverse agonists in asthma. Curr Opin Pharmacol 10: 254-259.
16. Drazen JM, Israel E, Boushey HA, Chinchilli VM, Fahy JV, Fish JE, et al,. (1996). Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. NEJM 335: 841-847. (Pubitemid 26304065)
17. Drotar DE, Davis EE, Cockcroft DW, (1998). Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 80: 31-34. (Pubitemid 28086752)
18. Finney P, Donnelly L, Belvisi M, Chuang T, Birrell M, Harris A, et al,. (2001). Chronic systemic administration of salmeterol to rats promotes pulmonary beta[2]-adrenoceptor desensitization and down-regulation of G(s alpha). Br J Pharmacol 132: 1261-1270. (Pubitemid 32234710)
19. Finney PA, Belvisi MG, Donnelly LE, Chuang T-T, Mak JCW, Scorer C, et al,. (2000). Albuterol-induced downregulation of Gsα accounts for pulmonary β2-adrenoceptor desensitization in vivo. J Clin Invest 106: 125-135. (Pubitemid 30437248)
20. Grove A, Lipworth BJ, (1995). Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet 346: 201-206.
21. Henry PJ, Goldie RG, (1990). Beta 1-adrenoceptors mediate smooth muscle relaxation in mouse isolated trachea. Br J Pharmacol 99: 131-135. (Pubitemid 20033798)
22. Henry PJ, Rigby PJ, Goldie RG, (1990). Distribution of beta 1- and beta 2-adrenoceptors in mouse trachea and lung: a quantitative autoradiographic study. Br J Pharmacol 99: 136-144. (Pubitemid 20033799)
23. Hollingsworth JW, Theriot BS, Li Z, Lawson BL, Sunday M, Schwartz DA, et al,. (2010). Both hematopoietic-derived and non-hematopoietic-derived β-arrestin-2 regulates murine allergic airway disease. Am J Respir Cell Mol Biol 43: 269-275.
24. Jackson CM, Lipworth B, (2004). Benefit-risk assessment of long-acting β2-agonists in asthma. Drug Safety 27: 243-270. (Pubitemid 38372904)
25. Jiang D, Liang J, Noble PW, (2007). Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23: 435-461.
26. Johnson M, (1998). The β-adrenoceptor. Am J Respir Crit Care Med 158: S146-S153.
27. Jokic R, Swystun VA, Davis BE, Cockcroft DW, (2001). Regular inhaled salbutamol. Chest 119: 370-375.
28. Kamachi A, Munakata M, Nasuhara Y, Nishimura M, Ohtsuka Y, Amishima M, et al,. (2001). Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 56: 19-24. (Pubitemid 32041714)
29. Kompa AR, Molenaar P, Summers RJ, (1995). Beta-adrenoceptor regulation and functional responses in the guinea-pig following chronic administration of the long-acting beta 2-adrenoceptor agonist formoterol. Naunyn Schmiedebergs Arch Pharmacol 351: 576-588.
30. Korosec M, Novak R, Myers E, Skowronski M, McFadden E, (1999). Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med 107: 209-213. (Pubitemid 29421585)
31. Kuhn C, Homer RJ, Zhu Z, Ward N, Elias JA, (2000). Morphometry explains variation in airway responsiveness in transgenic mice overexpressing interleukin-6 and interleukin-11 in the lung. Chest 117 (5 Suppl. 1): 260S-262S. (Pubitemid 30326980)
32. Levitt R, Mitzner W, (1988). Expression of airway hyperreactivity to acetylcholine as a simple autosomal recessive trait in mice. FASEB J 2: 2605-2608.
33. Lipworth B, Tan S, Devlin M, Aiken T, Baker R, Hendrick D, (1998). Effects of treatment with formoterol on bronchoprotection against methacholine. Am J Med 104: 431-438. (Pubitemid 28274846)
34. Loza MJ, Foster S, Peters SP, Penn RB, (2008). Interactive effects of steroids and beta-agonists on accumulation of type 2 T cells. J Allergy Clin Immunol 121: 750-755.
35. Lundblad L, Rinaldi L, Poynter M, Riesenfeld E, Wu M, Aimi S, et al,. (2011). Detrimental effects of albuterol on airway responsiveness requires airway inflammation and is independent of beta-receptor affinity in murine models of asthma. Respir Res 12: 27-38.
36. McGraw DW, Forbes SL, Mak JCW, Witte DP, Carrigan PE, Leikauf GD, et al,. (2000). Transgenic overexpression of beta 2-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. Am J Physiol Lung Cell Mol Physiol 279: L379-L389.
37. McGraw DW, Almoosa KF, Paul RJ, Kobilka BK, Liggett SB, (2003). Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J Clin Invest 112: 619-626. (Pubitemid 38056346)
38. McParland B, Macklem P, Pare P, (2003). Airway wall remodeling: friend or foe? J Appl Physiol 95: 426-434. (Pubitemid 36753828)
39. Newnham DM, McDevitt DG, Lipworth BJ, (1994). Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med 97: 29-37. (Pubitemid 24223631)
40. Newnham DM, Grove A, McDevitt DG, Lipworth BJ, (1995). Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients. Thorax 50: 497-504.
41. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, et al,. (2008). Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol 38: 256-262. (Pubitemid 351567693)
42. Nguyen LP, Lin R, Parra S, Omoluabi O, Hanania NA, Tuvim MJ, et al,. (2009). β2-Adrenoceptor signaling is required for the development of an asthma phenotype in a murine model. Proc Natl Acad Sci U S A 106: 2435-2440.
43. Nishimura K, Tamaoki J, Isono K, Aoshiba K, Nagai A, (2002). β-adrenergic receptor-mediated growth of human airway epithelial cell lines. Eur Respir J 20: 353-358.
44. Packer M, (1989). Is activation of the sympathetic nervous system beneficial or detrimental to the patient with chronic heart failure? Lessons learned from clinical trials with beta-adrenergic agonists and antagonists. J Cardiovasc Pharmacol 14 (Suppl. 5): S38-S43. (Pubitemid 19237359)
45. Pearce N, Beasley R, Crane J, Burgess C, Jackson R, (1995). End of the New Zealand asthma mortality epidemic. Lancet 345: 41-44.
46. Penn RB, Benovic JL, (2008). Regulation of heterotrimeric G protein signaling in airway smooth muscle. Proc Am Thorac Soc 5: 47-57.
47. Petrofski JA, Koch WJ, (2003). The β-adrenergic receptor kinase in heart failure. J Mol Cell Cardiol 35: 1167-1174. (Pubitemid 37163522)
48. Proskocil BJ, Fryer AD, (2005). β2-agonist and anticholinergic drugs in the treatment of lung disease. Proc Am Thorac Soc 2: 305-310. (Pubitemid 41566940)
49. Remington TL, Digiovine B, (2005). Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 11: 74-78. (Pubitemid 40189255)
50. Riesenfeld E, SulliVan M, Thompson-Figueroa J, Haverkamp H, Lundblad L, Bates J, et al,. (2010). Inhaled salmeterol and/or fluticasone alters structure/function in a murine model of allergic airways disease. Respir Res 11: 22-32.
51. Rohrer DK, Chruscinski A, Schauble EH, Bernstein D, Kobilka BK, (1999). Cardiovascular and metabolic alterations in mice lacking both β1- and β2-adrenergic receptors. J Biol Chem 274: 16701-16708.
52. Salpeter S, Buckley N, Ormiston T, Salpeter E, (2006). Meta-analysis: effect of long-acting {beta}-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med 144: 904-912. (Pubitemid 46768131)
53. Schuessler TF, Bates JHT, (1995). A computer-controlled research ventilator for small animals: design and evaluation. IEEE Trans Biomed Eng 42: 860-866.
54. Sears MR, (2002). Adverse effects of [beta]-agonists. J Allergy Clin Immun 110 (6 Part 2): S322-S328.
55. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al,. (1992). The use of β-agonists and the risk of death and near death from asthma. NEJM 326: 501-506.
56. Stolley PD, Schinnar R, (1978). Association between asthma mortality and isoproterenol aerosols: a review. Prev Med 7: 519-538. (Pubitemid 9113632)
57. Sugiura H, Liu X, Duan F, Kawasaki S, Togo S, Kamio K, et al,. (2007). Cultured lung fibroblasts from ovalbumin-challenged 'asthmatic' mice differ functionally from normal. Am J Respir Cell Mol Biol 37: 424-430. (Pubitemid 47502717)
58. Tamaoki J, Yamauchi F, Chiyotani A, Yamawaki I, Takeuchi S, Konno K, (1993). Atypical beta-adrenoceptor- (beta 3-adrenoceptor) mediated relaxation of canine isolated bronchial smooth muscle. J Appl Physiol 74: 297-302. (Pubitemid 23059760)
59. Tamaoki J, Tagaya E, Kawatani K, Nakata J, Endo Y, Nagai A, (2004). Airway mucosal thickening and bronchial hyperresponsiveness induced by inhaled β2-agonist in mice. Chest 126: 205-212. (Pubitemid 38943139)
60. Taylor DR, (2009). The {beta}-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 179: 976-978.
61. Teder P, Vandivier RW, Jiang D, Liang J, Cohn L, Puré E, et al,. (2002). Resolution of lung inflammation by CD44. Science 296: 155-158. (Pubitemid 34280077)
62. 2-induced inhibition of lung septation. Am J Physiol Lung Cell Mol Physiol 283: L971-L980. (Pubitemid 35204889)
63. Vignola AM, Mirabella F, Costanzo G, Di Giorgi R, Gjomarkaj M, Bellia V, et al,. (2003). Airway remodeling in asthma. Chest 123 (3 Suppl.): 417S-422S. (Pubitemid 36315442)
64. Walker JKL, Peppel K, Lefkowitz RJ, Caron MG, Fisher JT, (1999). Altered airway and cardiac responses in mice lacking G protein-coupled receptor kinase 3. Am J Physiol Regul Integr Comp Physiol 276: R1214-R1221. (Pubitemid 29214198)
65. Walker JKL, Fong AM, Lawson BL, Savov JD, Patel DD, Schwartz DA, et al,. (2003). β-Arrestin-2 regulates the development of allergic asthma. J Clin Invest 112: 566-574. (Pubitemid 38056341)
66. Walker JKL, Penn RB, Hanania NA, Dickey BF, Bond RA, (2011). New perspectives regarding β2-adrenoceptor ligands in the treatment of asthma. Br J Pharmacol 163: 18-28.
67. Wilding P, Clark M, Coon JT, Lewis S, Rushton L, Bennett J, et al,. (1997). Effect of long term treatment with salmeterol on asthma control: a double blind, randomised crossover study. BMJ 314: 1441-1446. (Pubitemid 27207933)